Risk factor
Strong trading liquidity
Profitability factor
Good growth
About
Eisai Co., Ltd. is a Japanese pharmaceutical firm deeply involved in the entire lifecycle of drug development, from initial research and innovation to manufacturing, distribution, and international trade within Japan. Its comprehensive product portfolio includes prominent medications such as Dayvigo, prescribed for insomnia, and the potent anticancer drug Lenvima, a molecularly targeted therapy effective against thyroid cancer, hepatocellular carcinoma, and renal cell carcinoma when paired with everolimus. The company also markets Methycobal for peripheral neuropathy and Halaven, another anticancer agent targeting breast cancer. Further offerings encompass Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid formulation; Goofice and Movicol, utilized for managing chronic constipation; Fycompa, an antiepileptic; Pariet, a proton-pump inhibitor; and Aricept, a treatment for Alzheimer's and Dementia with Lewy bodies. Additionally, it produces Chocola BB plus, a vitamin B2 supplement. Eisai maintains a strategic alliance with Bristol Myers Squibb, focusing on the joint development and commercialization of the antibody drug conjugate, farletuzumab ecteribulin. Established in Tokyo, Japan, in 1941, the company was initially known as Nihon Eisai Co., Ltd. before adopting its current name, Eisai Co., Ltd., in 1955.
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, of fair value on EV/EBIT
Target Price
The average target price of 4523.T is 4477 and suggests 12.2% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to